Hong J.,China Marrow Donor Program
Clinical transplants | Year: 2011
There are about 50,000 new leukemia patients each year in China. The Chinese government has funded the CMDP since 2001. So far, there are 1,471,212 volunteer donors registered in CMDP with HLA-A, B, DR typing. Of the donors, 25.85% were typed with high-resolution results. The typing error rate has decreased from 8.18% in 2003, to 0.4% in 2011. So far, 2,700 patients, including patients outside of China, have received stem cells from the CMDP. The overall one-year survival is about 70%. Since 2006, 42% of patients have received HLA-A, B, C, DR, DQ identical (10/10) transplants and 37.5% of patients have received 9/10 transplants. The one-year survival with 10/10 is 71% and 72% for 9/10 transplants. The efforts of the past 10 years have laid a foundation for the CMDP's further development. We expect that more patients' lives will be saved through these efforts.
Zhou M.,BGI Diagnosis Co. |
Gao D.,China Marrow Donor Program |
Chai X.,BGI Diagnosis Co. |
Liu J.,China Marrow Donor Program |
And 20 more authors.
Tissue Antigens | Year: 2015
Next generation sequencing (NGS)-based human leukocyte antigen (HLA) typing was used for ultra large-scale genotyping of registry donors for the China Marrow Donor Program (CMDP). More than 79,000 samples were subjected to HLA genotyping at 4-digit allelic level without ambiguities for HLA-A, -B, -C, DRB1 and DQB1 loci, with throughput up to 2068 samples per lane in a HiSeq flow cell (eight lanes per run), and cost reduced by 95% compared with that of Sanger-based typing. Two percent of randomly selected samples were quality control (QC) tested at 4-digit allelic level by the CMDP QC laboratory, yielded a concordance of 99.72%. These results demonstrate that NGS is a cost effective and valuable tool for HLA typing of registry donors. © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.